Anyeep, a Suzhou-based developer of mass spectrometers, has reportedly raised close to RMB 100 million (USD 13.96 million) in a Series A financing round. The round was led by Greenriver Capital, with participation from Dunhang Investment, PEAKVEST FOF, and existing investors Frees Fund and Yuanbio Venture Capital. The proceeds will be used to accelerate the industrialization and market filing for its clinical ultra-high performance liquid chromatography tandem mass spectrometry system, as well as to support R&D of hardware, software, and core components of clinical mass spectrometry and expand its industrialization team.
Company Profile and Pipeline
Founded in 2016, Anyeep has developed a range of mass spectrometers for medical detection, laboratory use, and portable applications. The company also holds multiple core patents. This funding will enable Anyeep to further enhance its product offerings and strengthen its position in the clinical mass spectrometry market.
Future Plans
With the new capital, Anyeep plans to ramp up the industrialization of its clinical mass spectrometry systems, expand its R&D capabilities, and enhance its market presence. This strategic move will help the company meet growing demand for advanced diagnostic tools and further solidify its position in the global mass spectrometry market.-Fineline Info & Tech
